David R Raleigh
Overview
Explore the profile of David R Raleigh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
3839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin K, Zou C, Hubbard A, Sengelmann S, Goudy L, Wang I, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39998382
Background: Glioblastoma (GBM) carries a poor prognosis, and new therapeutic strategies are necessary to improve outcomes for patients with this disease. Alkylating chemotherapies including temozolomide (TMZ) and lomustine (CCNU) are...
2.
Kahr J, Stein K, John P, Walles T, Roepke M, Neyazi B, et al.
Clin Neuropathol
. 2025 Feb;
PMID: 39969396
Distant metastases in meningioma are rare, and the molecular drivers of meningioma spread are not well understood. We describe the case of a 63-year-old woman who was diagnosed with an...
3.
Khoroshkin M, Zinkevich A, Aristova E, Yousefi H, Lee S, Mittmann T, et al.
bioRxiv
. 2025 Jan;
PMID: 39803435
mRNA delivery offers new opportunities for disease treatment by directing cells to produce therapeutic proteins. However, designing highly stable mRNAs with programmable cell type-specificity remains a challenge. To address this,...
4.
5.
Morshed R, Nguyen M, Choudhury A, Al-Adli N, Magill S, Haddad A, et al.
Neurosurgery
. 2025 Jan;
PMID: 39773932
Background And Objectives: Extent of resection (EOR) is prognostic for meningioma outcomes. DNA methylation profiling can shed light on biological drivers and therapeutic vulnerabilities. The goal of this study was...
6.
Perlow H, Raleigh D, Wang T, Pollom E, Milano M, Breen W, et al.
Int J Radiat Oncol Biol Phys
. 2024 Dec;
PMID: 39701546
Purpose: Meningiomas are the most common primary intracranial tumor. Somatostatin receptor 2 is almost universally expressed in meningioma tissue. For patients who require adjuvant radiation, somatostatin receptor based (68)Ga-DOTATATE positron...
7.
Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, Jenkinson M, et al.
Neuro Oncol
. 2024 Nov;
PMID: 39577862
Meningiomas are the most common primary intracranial tumors of adults. For meningiomas that progress or recur despite surgical resection and radiotherapy, additional treatment options are limited due to lack of...
8.
Lucas C, Al-Adli N, Young J, Gupta R, Morshed R, Wu J, et al.
Neuro Oncol
. 2024 Nov;
27(1):89-105.
PMID: 39560080
Background: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous...
9.
Walsh K, Price M, Raleigh D, Calabrese E, Kruchko C, Barnholtz-Sloan J, et al.
J Natl Cancer Inst
. 2024 Oct;
117(2):366-374.
PMID: 39392420
Background: Meningioma risk factors include older age, female sex, and being Black/African American. Limited data explore how meningioma risk in individuals who are Black varies across the lifespan, interacts with...
10.
Terry M, Nguyen M, Tang V, Guney E, Bharani K, Dahiya S, et al.
Endocr Pathol
. 2024 Oct;
35(4):338-348.
PMID: 39388031
Pituitary neuroendocrine tumors (PitNET) that metastasize comprise ~ 0.2% of adenohypophyseal tumors are aggressive and are challenging to treat. However, many non-metastatic tumors are also aggressive. Herein, we review 21...